Evidence map›Paper›PMID 30181870›Full record

ArticleAntimicrobial resistance and infection control2018

Characteristics of glycopeptide-resistant

Ksenia Szymanek-Majchrzak, Andrzej Mlynarczyk, Grazyna Mlynarczyk

Abstract read
In one paragraph

Article in Antimicrobial resistance and infection control, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Antimicrobial Resistance ofAntibiotics (Basel, Switzerland) · 2023
    Article
  7. Reduction of methicillin-resistantFrontiers in cellular and infection microbiology · 2023
    Article
  8. Open life sciences · 2023
    Article
  9. Teicoplanin associated geneFrontiers in microbiology · 2023
    Article
  10. Infection and drug resistance · 2023
    Article
  11. Antibiotic Resistance in Bacteria-A Review.Antibiotics (Basel, Switzerland) · 2022
    Review
  12. Genomic Insights of FirstInternational journal of molecular sciences · 2022
    Article
  13. Molecular Mechanisms of Drug Resistance inInternational journal of molecular sciences · 2022
    Review
  14. Article
  15. Sanguiin H-6 Fractionated from Cloudberry (Antibiotics (Basel, Switzerland) · 2021
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ksenia Szymanek-Majchrzak1Department of Medical Microbiology, Medical University of Warsaw, T. Chalubinskiego 5 Str, 02-004 Warsaw, Poland.ORCID 0000-0003-4314-3522
Andrzej MlynarczykDepartment of Medical Microbiology, The Infant Jesus Teaching Hospital, Lindleya 4 Str, 02-005 Warsaw, Poland.
Grazyna Mlynarczyk1Department of Medical Microbiology, Medical University of Warsaw, T. Chalubinskiego 5 Str, 02-004 Warsaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Vancomycin is still one of the most commonly used drug for treatment of severe methicillin-resistant Methods: Among 600 HA-MRSA strains, isolated from patients with symptomatic infections, 47 were subjected to detailed analysis. In the study, mechanisms behind VRSA phenotypes were determined (E-tests, GRD-test, agar-dilution method and Results: In general population of studied strains, 11/47 (23.4%) were VRSA and 36/47 (76.6%) were resistant only to teicoplanin. All isolates exhibited Conclusions: VRSA strains isolated from patients hospitalized at three Warsaw teaching hospitals in Poland, over a period of 17-years do not pose a threat as potential donors of

Indexed as

Cross InfectionHospitals, TeachingInpatientsAnti-Bacterial AgentsGenes, BacterialGenotypeHumansMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsMultilocus Sequence TypingPhenotypePolandStaphylococcal InfectionsVancomycinAnti-Bacterial AgentsVancomycinMLSTSCCmecStaphylococcus aureusTeicoplaninTRSAVancomycinVRSA

Identifiers

PMID30181870
PMCPMC6114487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.